BioSpace News Archive

Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock.

Fulcrum Therapeutics, Inc.®, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced the appointment of Alan A. Musso as chief financial officer, effective August 7, 2023.

NeuBase Therapeutics, Inc., a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, announced that its Board of Directors has completed a review of the Company’s business, including the status of its programs, resources, and capabilities.

BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, and bit.bio, the company coding human cells for novel cures, today announced a collaboration and option agreement for the discovery and manufacture of iPSC-derived regulatory T cells (Tregs) for use in creating therapeutics.

Aurinia Pharmaceuticals Inc. issued its financial results for the three and six months ended June 30, 2023.

Agios Pharmaceuticals, Inc. has entered into an exclusive worldwide license agreement with Alnylam Pharmaceuticals, Inc. under which Agios will acquire the rights to develop and commercialize Alnylam’s novel preclinical siRNA targeting TMPRSS6, as a potential disease-modifying treatment for patients with polycythemia vera.